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Abstract
Background: Postpartum haemorrhage (PPH) is the leading cause of maternal mortality in low-income countries
and contributes to nearly a quarter of maternal deaths globally. The current available interventions for prevention of
postpartum haemorrhage, oxytocin and carbetocin, are limited by their need for refrigeration to maintain potency,
as the ability to maintain a cold chain across the drug distribution and storage network is inconsistent, thus
restricting their use in countries with the highest burden of maternal mortality. We describe a randomized,
double-blind non-inferiority trial comparing a newly developed room temperature stable formulation of carbetocin
to the standard intervention (oxytocin) for the prevention of PPH after vaginal birth.
Methods/design: Approximately 30,000 women delivering vaginally will be recruited across 22 centres in 10 countries.
The primary objectives are to evaluate the non-inferiority of room temperature stable carbetocin (100 μg intramuscular)
versus oxytocin (10 IU intramuscular) in the prevention of PPH and severe PPH after vaginal birth. The primary
endpoints are blood loss ≥500 mL or the use of additional uterotonics (composite endpoint required by drug
regulatory authorities) and blood loss ≥1,000 mL (WHO requirement). Non-inferiority will be assessed using a two-sided
95 % confidence interval for the relative risk of the above endpoints for room temperature stable carbetocin versus
oxytocin. The upper limit of the two-sided 95 % confidence interval for the relative risk for the composite endpoint of
blood loss ≥500 mL or the use of additional uterotonics, and for the endpoint of blood loss ≥1,000 mL, will be
compared to a non-inferiority margin of 1.16 and 1.23, respectively. If the upper limit is below the corresponding
margin, non-inferiority will have been demonstrated. The safety analysis will include all women receiving treatment.
Safety and tolerability will be assessed by a review of adverse events, by conducting inferential testing with significance
levels for between-group comparisons.
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Discussion: If the results of the study show that room temperature stable carbetocin is a safe and effective alternative
to oxytocin, this could have a substantial impact on the prevention of postpartum haemorrhage and maternal survival
worldwide.
Trial registration: ACTRN12614000870651 (14 August 2014)
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Background
Postpartum haemorrhage (PPH) is defined as a blood
loss of ≥500 mL within 24 hours of delivery, while severe
PPH (sPPH) is defined as a blood loss of ≥1,000 mL
within the same time frame [1]. PPH is the leading cause
of maternal mortality in low-income countries, contrib-
uting to nearly a quarter of maternal deaths globally. In
addition, PPH is a significant contributor to severe ma-
ternal morbidity and long-term disability, as well as to a
number of other severe maternal conditions generally
associated with more substantial blood loss, including
shock and organ dysfunction [2–4]. Improving health
care for women during childbirth in order to prevent
and treat PPH is an essential step towards the achieve-
ment of the United Nations Millennium Development
Goals.
The majority of deaths due to PPH could be avoided
through the use of prophylactic uterotonics during the
third stage of labour and by timely and appropriate man-
agement. Injectable oxytocin has been recommended by
the World Health Organization (WHO) for routine use
during the third stage of labour and is the preferred drug
for the prevention and management of blood loss after
childbirth; however, several studies have demonstrated
that oxytocin loses potency in field conditions, particu-
larly in tropical climates [1, 5, 6]. To decrease potency
loss due to degradation, oxytocin must be either stored
at controlled room temperature (25 °C or lower) for a
restricted amount of time or refrigerated (2 °C to 8 °C),
making its use difficult in low resource settings. To ease
this barrier, several groups have been researching heat
stable oxytocin formulations [5]. Though some progress
has been made in this area, there is currently no heat
stable oxytocin formulation for therapeutic use [7].
Carbetocin (1-deamino-1-monocarba-(2-O-methyl-
tyrosine)-oxytocin) is a long-acting synthetic agonist
analogue of the human oxytocin, and it appears to be a
promising agent in the prevention of PPH following va-
ginal delivery. The clinical and pharmacological properties
of carbetocin are similar to those of oxytocin. However,
carbetocin is a more stable molecule and induces a pro-
longed uterine response, when administered postpartum,
in terms of both amplitude and frequency of contractions
due to its longer half-life [8–10]. In a Cochrane systematic
review including 11 studies (2,635 women), the use of
carbetocin resulted in a statistically significant reduction
in the use of additional/therapeutic uterotonics compared
to oxytocin for those who underwent caesarean delivery
(risk ratio (RR) 0.62; 95 % confidence interval (CI) 0.44 to
0.88; four trials, 1,173 women), but not for vaginal deliv-
ery. Compared to oxytocin, carbetocin was associated with
reduced uterine massage following both caesarean delivery
(RR 0.54; 95 % CI 0.37 to 0.79; two trials, 739 women) and
vaginal delivery (RR 0.70; 95 % CI 0.51 to 0.94; one trial,
160 women). There were no statistically significant differ-
ences between carbetocin and oxytocin in terms of risk of
any PPH or in risk of sPPH [11].
Carbetocin is currently approved in multiple countries
for the prevention of PPH during caesarean section. The
drug is licensed to be administered by slow intravenous
(IV) single injection at a dose of 100 μg. Its current for-
mulation requires refrigeration.
A room temperature stable (RTS) variant of carbetocin
has recently been developed and is now approved in the
European Union; this variant differs from the current
carbetocin formulation only in its excipients (Table 1).
The stability data from long-term studies performed at
30 °C and 75 % relative humidity, as well as accelerated
at 40 °C and 75 % relative humidity, indicate a shelf life
of at least 36 months at 30 °C for the new RTS formula-
tion of carbetocin. Carbetocin RTS therefore represents
a promising intervention for reducing PPH, particularly
in settings where cold storage is difficult to achieve and
maintain. Here, we describe a planned randomized trial
to evaluate the non-inferiority of carbetocin RTS versus
oxytocin after vaginal delivery in the prevention of PPH
and sPPH.
Methods/design
Primary objectives and hypotheses
The trial has two primary objectives: 1) To evaluate
non-inferiority of carbetocin RTS versus oxytocin after
vaginal delivery in the prevention of the composite end-
point “blood loss of 500 mL or more or the use of add-
itional uterotonics” at one hour and up to two hours for
women who continue to bleed after one hour; and 2) to
evaluate non-inferiority of carbetocin RTS versus oxyto-
cin in the prevention of sPPH (≥1,000 mL blood loss) at
one hour and up to two hours for women who continue
to bleed after one hour.
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For both objectives the hypotheses are: 1) carbetocin
RTS is non-inferior to oxytocin in terms of the propor-
tion of women with blood loss ≥500 mL or the use of
additional uterotonic drugs after vaginal delivery within
a non-inferiority margin of 1.16 on the relative risk scale,
and the proportion of women with blood loss ≥1,000 mL
after vaginal delivery within a non-inferiority margin of
1.23 on the relative risk scale; and 2) carbetocin RTS is
superior to oxytocin in terms of the proportion of women
with blood loss ≥500 mL or use of additional uterotonic
drugs, and in terms of the proportion of women with
blood loss ≥1,000 mL after vaginal delivery. For each of
the two primary endpoints, superiority will be tested if
non-inferiority has been demonstrated.
Investigators and other assessors will be blinded to in-
dividual treatment allocation. The study will be con-
ducted by the HRP/WHO, and WHO staff will also
remain blinded to individual participant treatment allo-
cation during the conduct of the trial.
Study drug
Carbetocin RTS (Ferring, St. Prex, Switzerland) will be
administered as a single IM dose of 100 μg in a 1 mL so-
lution. Oxytocin 10 IU/mL (Syntocinon®, Novartis, Basel,
Switzerland) will be administered as a single intramuscu-
lar (IM) dose in a 1 mL solution. In order to maintain
the blindness of the trial, carbetocin RTS and oxytocin
will be provided in 1 mL ampoules in consecutively
numbered treatment packs arranged in dispensers and
will be stored in a refrigerator at 2 °C to 8 °C.
Study design
This clinical trial will be conducted in compliance with the
clinical trial protocol, good clinical practice and the applic-
able regulatory requirements. The trial is planned to be
conducted at 22 centres in 10 countries: Argentina, Egypt,
India, Kenya, Nigeria, Singapore, South Africa, Thailand,
Uganda and the United Kingdom. Approximately 30,000
women will be included in the trial. The recruitment period
will be approximately 12 months in each country.
The care provider in charge of antenatal care visits at
the hospital will inform potentially eligible pregnant
women (women with no allergies to carbetocin, other
oxytocin homologues or excipients, or serious cardiovas-
cular disorders) about the trial.
At admission for labour at the hospital, the woman will
be approached for participation in the trial when she is in
early labour and if her vital signs are normal, and she is
not stressed. The investigator will invite her to sign the in-
formed consent. Informed consent will be obtained before
any trial-related procedures are carried out.
During the second stage of labour when vaginal delivery
is imminent, the woman will be randomized to receive
either a single dose of oxytocin 10 IU IM or a single dose
of carbetocin RTS 100 μg IM.
The investigator will administer the investigational
medicinal product (IMP) immediately after the birth of
the baby (preferably within one minute). Once the IMP
has been administered, the investigator will follow the
management of the third stage of labour as recom-
mended in WHO guidelines and as detailed in the trial’s
manual of operations.
Once the cord is clamped (1–3 minutes after delivery
of the baby) and cut, the investigator will place a cali-
brated drape under the woman’s buttocks and blood loss
will be measured for one hour or two hours postpartum
if the bleeding continues beyond one hour (blood loss
measuring details are provided in the trial’s manual of
operations).
The woman will end her participation in the trial after
her discharge or if she is transferred to a higher care
unit, such as an intensive care unit (ICU). Data will be
entered into a validated online database system compli-
ant with the FDA 21 CFR part 11.
The trial master protocol was approved by the World
Health Organization Research Ethics Review Committee.
All sites received ethics approval from their institu-
tional/national boards (see additional file 1 for the list
of ethics committees that reviewed and approved the
proposal).
Table 1 Composition of carbetocin RTS and carbetocin
New carbetocin RTS formulation Current carbetocin refrigerated formulation (Duratocin®, Ferring)a
Component Amount (mg/mL) Function Component Amount (mg/mL Function
Carbetocin 0.100 Active substance Carbetocin 0.100 Active substance
Succinic acid 1.19 Buffer Sodium chloride 9 Isotonicity agent
Mannitol 47.0 Isotonicity agent Glacial acetic acid to pH 3.8 pH adjustment
L-methionine 1.00 Antioxidant Water for injection 1.0 mL Solvent
Sodium hydroxide 2 N to pH 5.45 pH adjustment – – –
Water for injection 1.0 mL Solvent – – –
aCarbetocin 100 μg/mL was first approved in Canada in June 1997 and is currently registered in more than 70 countries under the trade
names PABAL/DURATOCIN/LONACTENE/DURATOBAL
RTS room temperature stable
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Inclusion/exclusion criteria
Women will be eligible for inclusion into this trial if they
are expected to deliver vaginally, have a cervical dilata-
tion equal to or less than 6 cm, have a known singleton
pregnancy and have provide written informed consent.
Women will not be eligible for study participation if
they: 1) are in an advanced first stage of labour (>6 cm
cervical dilatation) or are too distressed to understand,
confirm and give informed consent regardless of cervical
dilatation; 2) are non-emancipated minors (as per local
regulations) without a guardian; 3) have been scheduled
for a planned caesarean section; 4) have a birth consid-
ered to be an abortion according to local guidelines; 5)
have known allergies to carbetocin, other oxytocin ho-
mologues or excipients in the medicinal products used
in the trial; 6) have serious cardiovascular disorders; 7)
have serious hepatic or renal disease; 8) have epilepsy; or
9) are not capable of giving consent due to other health
problems such as obstetric emergencies (for example,
antepartum haemorrhage) or mental disorder.
Participants will be free to discontinue the trial at any
time without giving their reason(s). Participants who
withdraw will not be replaced; that is, randomized num-
bers will be uniquely linked to each participant. Data
collected up to that point will be included unless partici-
pants request the opposite. After a participant has com-
pleted the trial or has withdrawn early, usual treatment
will be administered, if required, in accordance with the
trial centre’s standard of care and generally accepted
medical practice and depending on the participant’s indi-
vidual medical needs.
Randomization
The random allocation sequence will be generated cen-
trally at WHO headquarters using computer-generated
random numbers. Randomization will be stratified by
country and will use permuted blocks, with an allocation
ratio of 1:1. Participants will randomly be assigned
within each country to one of the two treatment groups:
oxytocin 10 IU IM or carbetocin RTS 100 μg IM. Alloca-
tion of the randomly generated sequence will be per-
formed by consecutively numbered treatment packs
arranged in dispensers.
Primary and secondary endpoints
The primary and secondary endpoints are listed in
Table 2. The trial is being conducted as an effectiveness
trial with the objective of carbetocin RTS being regis-
tered for the indication “prevention of postpartum
haemorrhage” by drug regulatory authorities if it is
shown to be non-inferior or superior to oxytocin. The
primary composite endpoint is blood loss ≥500 mL or
use of additional uterotonics. For the purpose of evaluat-
ing clinical effectiveness and for the potential inclusion
of carbetocin RTS in future WHO guidelines and the
Model List of Essential Medicines, the more substantive
endpoint of blood loss ≥1,000 mL is also a primary end-
point. Since the two primary endpoints serve independ-
ent objectives, there will be no adjustment for the type I
error rate for multiplicity of endpoints.
Assessment of efficacy
Efficacy will be assessed using blood loss volume meas-
urement per the two primary endpoints listed in Table 2.
Blood loss will be measured using a calibrated drape
[12], which will be placed under the participant’s buttocks
once the cord is clamped (1–3 minutes after delivery of
the baby) and cut. Blood loss will be measured for one
hour, or for two hours postpartum, if the bleeding con-
tinues beyond one hour. Blood loss weight in grams will
be converted to millilitres by dividing the figure in grams
by 1.06 (blood density in grams per millilitre) [13].
Assessment of safety
Comprehensive assessment of the safety of the study
drugs will be performed throughout the course of the
trial, from the time of the participant’s signature of in-
formed consent until discharge. Trial centre personnel
will report any adverse event (AE), whether observed by
the investigator or reported by the participant.
Table 2 Primary and secondary endpoints
Primary endpoints
The proportion of women:
• with blood loss of 500 mL or more or the use of additional
uterotonics at one hour and up to two hours for women who
continue to bleed after one hour;
• with blood loss of 1,000 mL or more at one hour and up to two
hours for women who continue to bleed after one hour.
Secondary endpoints
The proportion of women:
• with blood loss of 500 mL or more at one hour (or two hours
postpartum if the bleeding continues beyond one hour);
• receiving additional uterotonics at one hour (or two hours
postpartum if the bleeding continues beyond one hour);
• receiving additional uterotonics up to time of discharge;
• receiving blood transfusion up to time of discharge;
• with manual removal of placenta up to time of discharge;
• having additional surgical procedures (for example, suturing of
cervix/high vaginal tear, exploration of uterine cavity under
general anaesthetic, uterine compression suture, uterine or
hypogastric ligation, hysterectomy) up to time of discharge;
• with maternal death;
• with composite outcome of maternal death or severe morbidity
(admission to intensive care unit, hysterectomy, blood loss of two
litres or more, uterine inversion) up to time of dischargeBlood loss
in mL at one hour (or two hours postpartum if the bleeding
continues beyond one hour).
The incidence and severity of adverse or serious adverse events
up to the time of discharge.
Newborn outcomes (vital status, Apgar score at 5 minutes,
resuscitation of the baby, mechanical ventilation).
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The intensity of an AE will be classified using a three-
point scale: mild ─ awareness of signs or symptoms,
but no disruption of usual activity; moderate ─ event
sufficient to affect usual activity; and severe ─ inability
to work or perform usual activities. AEs will also be clas-
sified as possibly related to study drug (that is, there is
evidence or argument to suggest a causal relationship
between the AE and the study drug), or not related to
study drug (that is, there is no reasonable evidence or
argument to suggest a causal relationship between the
AE and the study drug).
The outcome of an AE will be classified as: recovered/
resolved (fully recovered or the condition has returned
to the level observed at initiation of trial treatment); re-
covered/resolved with sequelae (resulted in persistent or
significant disability/incapacity); recovering/resolving;
not recovered/not resolved; or fatal.
An AE will be considered serious if it results in death,
is life-threatening, requires in-patient hospitalization or
prolongation of existing hospitalization, results in per-
sistent or significant disability/incapacity, is a congenital
anomaly/birth defect, or is an important medical event.
If an investigator becomes aware of a serious AE after
the participant’s hospital discharge, and he/she assesses
the serious AE to have a reasonable possible causality to
the study drug, the case will be reported, regardless of
how long after the end of the trial the AE took place.
Since the amount of blood lost is collected as an effi-
cacy endpoint, only the following blood loss events that
fulfil the criteria for a serious AE will be recorded: ICU
admission (adult ICU admission, not maternity/labour
ward high care); surgical intervention for control of haem-
orrhage (hypogastric artery ligation or uterine compression
sutures); peripartum hysterectomy, blood loss ≥ 2,000 mL;
and uterine inversion.
Sample size calculation
The two endpoints that guided the sample size estima-
tion for the trial were sPPH (blood loss ≥1,000 mL),
PPH (blood loss ≥500 mL) or the use of additional
uterotonics. Severe PPH is a more serious endpoint that
is closely associated to severe maternal morbidity and
related to additional interventions. The sPPH endpoint
is also less frequent and thus guided the overall sample
size estimation.
A non-inferiority design was chosen since the aim of
the trial is to determine if carbetocin RTS is non-inferior
in efficacy to the standard intervention (oxytocin 10 IU
IM). In order to demonstrate non-inferiority within a
margin of 0.46 %, with a power of 80 % and with a sig-
nificance level of 2.5 %, a total of 29,082 women are
needed assuming an equal sPPH prevalence of 2 % with
both treatments, calculated by the standard formula (see
Additional file 2 for the rationale of the choice of the
margin) [14]. The margin of 0.46 % on the difference
scale corresponds to 1.23 on the relative scale for the as-
sumed prevalence. Figure 1 shows the total sample size re-
quired to assess non-inferiority at the 2.5 % level of
significance (usually required for non-inferiority trials) for
different scenarios. We also assumed, from a similar large
trial [15], a 3 % loss of study participants who are eligible
to contribute to the analysis due to exclusion of women
Fig. 1 Total sample size for non-inferiority with equal proportions = 1.5 % or 2 %, 80 % power and different values of the margin on the relative scale
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with a caesarean section or abortion after randomization,
and those who are not protocol-compliant (excluded only
in the per-protocol analysis), bringing the sample size to
30,000. This sample size will provide 90 % power for a
conventional two-sided 5 % test of superiority to detect a
minimum significant difference between 1.5 % and 2 % in
the rate of sPPH for the two treatment groups.
Similarly, we calculated the sample size for the compos-
ite endpoint defined as blood loss ≥500 mL or administra-
tion of additional uterotonics. With active management,
the risk of this event is estimated as 16 % (personal com-
munication) [15]. Assuming equal prevalence for this
event of 16 % with both treatments, in order to demon-
strate non-inferiority within a margin of 1.16 on the rela-
tive scale, with a power of 80 % and with a significance
level of 2.5 %, a total of 6,242 women are needed. With
30,000 women the power obtained would be more than
99 % [14]. This sample size will provide a power of 99.5 %
for a conventional two-sided 5 % test of superiority to
detect a minimum significant difference between 16 %
and 18 % in the occurrence of PPH or administration of
additional uterotonics for the two treatment groups
(Stata version 13.1).
Analysis populations
Analyses will be performed in three populations:
intention-to-treat (ITT), modified ITT, and per-protocol.
The ITT population includes all randomized partici-
pants, using the treatment as randomized. The modified
ITT analysis excludes women having a caesarean section
after randomization and those withdrawing consent. The
per-protocol population includes all participants ran-
domized into the trial, who were compliant with, and
treated according to, the protocol, and who fulfil the fol-
lowing criteria: compliance with all entry criteria, ab-
sence of major clinical trial protocol violations with
respect to factors likely to affect the efficacy of treat-
ment, and adequate compliance with trial medication
(giving oxytocin or carbetocin to women as random-
ized). Declaring carbetocin RTS non-inferior to oxytocin
will require non-inferiority to be demonstrated for both
per-protocol and the modified ITT analyses. For testing
the superiority of each endpoint, the modified ITT ana-
lysis will be the main analysis. The primary population
for safety analysis will consist of all women receiving
treatment.
Statistics
Safety and tolerability will be assessed by a review of
AEs, by conducting inferential testing with significance
levels for between-group comparisons. The between-
treatment difference for the occurrence of AEs will be
tested using the stratified Mantel-Haenszel chi-square if
frequencies are sufficiently high, or otherwise with exact
methods taking stratification into account.
For efficacy, non-inferiority will be assessed using a
two-sided 95 % confidence interval (CI) for the relative
risk (RR) of sPPH and of PPH or additional uterotonic
use (carbetocin RTS versus oxytocin). The upper limit of
the two-sided 95 % CI for the RR for the composite end-
point of blood loss ≥500 mL or additional uterotonic use
will be compared to the non-inferiority margin of 1.16.
The upper limit of the two-sided 95 % CI for the RR for
the endpoint of blood loss ≥1,000 mL will be compared
to the non-inferiority margin of 1.23. If the upper limit
is below the corresponding margin, non-inferiority will
have been demonstrated. This upper limit is the same as
the upper limit of the one-sided 97.5 % CI; therefore, the
significance level for the non-inferiority test will be
2.5 % (one-sided). For each endpoint, to declare carbeto-
cin RTS non-inferior to oxytocin, we will require non-
inferiority to be demonstrated for both PP and the
modified ITT analyses. If non-inferiority is demon-
strated, a two-tailed superiority test will be conducted at
5 % level of significance. Interpretation will be as in Fig. 1
of Piaggio et al. [16]. Comparisons will also be expressed
as risk differences with 95 % CIs.
The statistical technique used to conduct tests and ob-
tain CIs for the main endpoints will be a logistic model
with a binary endpoint, a binomial distribution and the
log link to obtain RRs. The identity link will be used to
obtain risk differences. Stratifying variables (country) will
be included in the model. The model will be fitted using
SAS Software version 9.3 (SAS Institute Inc., Cary, NC,
USA). A separate model will be fitted for each of the
two primary endpoints.
We will use the RR as measure of treatment effect on
the relative scale for the two primary endpoints. For the
composite endpoint of blood loss ≥500 mL or use of add-
itional uterotonics, the margin has been justified as 1.2 on
the odds ratio (OR) scale and 1.16 on the RR scale. Het-
erogeneity across centres will be assessed by using a term
in the logistic model for the interaction between treatment
and centres. If there is heterogeneity between the centres
for any of the results, the possible causes will be explored.
The secondary binary endpoints of blood loss
≥500 mL, use of additional uterotonics, blood transfu-
sion, manual removal of placenta, additional surgical
procedures, maternal death and the composite endpoint
of maternal death or severe morbidity, will be analysed
using the modified ITT population and will be assessed
only for conventional superiority using risk differences
and relative risks with 95 % CIs estimated with the same
techniques described for the main endpoints.
The secondary outcome of blood loss in millilitres will
be analysed using the log transformation. This is based
on the following: 1) the blood loss distribution is
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positively skewed; 2) different distributions were fitted to
blood loss data from a large trial [15] and the lognormal
distribution was found to have a very good fit (personal
communication); and 3) the lognormal distribution was
used for blood loss data in the literature [13]. Therefore,
a lognormal distribution will be fitted to the blood loss
data and the probabilities of blood loss ≥500 mL and of
≥1,000 mL will be compared between treatments using
parametric methods. The quantiles will be compared be-
tween treatments using quantile regression [17].
Trial oversight
The trial will be overseen by two committees. The Trial
Steering Committee (TSC) is composed of the WHO/
HRP coordination team, investigators from the 10 par-
ticipating countries and five independent members with
expertise in clinical, statistical and scientific disciplines.
The TSC should provide oversight of the progress of the
trial and ensure the trial is conducted in accordance
with the principles of good clinical practice (GCP).
The Data and Safety Monitoring Committee (DSMC),
with no direct involvement in the trial, will handle any
ethical issues that may arise while the trial is in progress
and will scrutinize two interim analyses, the first to look
at safety when 5,000 participants have been recruited,
and the second conducted when 15,000 women have
been recruited to look at both safety and efficacy. The
interim analyses will be masked to trial investigators,
trial statistician, WHO, Merck for Mothers and Ferring
staff, but not to DSMC members. The DSMC will be ex-
pected to provide an ongoing risk-benefit evaluation that
addresses the uncertainty necessary to continue.
Discussion
PPH is one of the major contributors to maternal mor-
tality and morbidity worldwide. Prevention of PPH is
therefore of great importance in the pursuit of improved
health care for women. The decision to proceed with a
large, randomized controlled trial to address this unmet
medical need by evaluating the effectiveness of carbeto-
cin RTS compared to oxytocin was based on several
considerations. This included the frequent concerns
about the quality of oxytocin and its stability in some
developing countries, the potential advantage of carbeto-
cin RTS due to its longer half-life (than that of oxytocin),
especially when administered intramuscularly, and its
heat stability. This study will be conducted under condi-
tions where both study drugs, oxytocin and carbetocin
RTS, will be kept under strict refrigeration. If the trial
meets its primary endpoint of non-inferiority to oxyto-
cin, the carbetocin RTS formulation will be made avail-
able in high-burden countries at an accessible public
sector price. This would have major implications for
expanding access to effective care and could have a sub-
stantial impact on maternal survival.
The risk-benefit relationship was carefully considered
in the planning of the trial, as was the selection of the
dose of carbetocin RTS. The selected dose for the carbe-
tocin RTS IM injection is 100 μg, the same as the dose
approved for IV injection following caesarean section.
The safety profile of a 100 μg dose of the carbetocin re-
frigerated formulation, when administered intravenously,
is derived from clinical studies as well as from pharmacov-
igilance activities that comprise nearly 5 million women
exposed. Reported AEs during clinical trials when adminis-
tered by IV after caesarean section under spinal or epidural
anaesthesia are headache, tremor, hypotension, flushing,
nausea, abdominal pain, pruritus, anaemia, dizziness, chest
pain, dyspnoea, metallic taste and vomiting. The AEs ob-
served were of the same type and frequency as those ob-
served with the comparator, oxytocin. In addition, efficacy
and safety data on 100 μg of the carbetocin refrigerated
formulation delivered intramuscularly during vaginal deliv-
ery is available from several published randomized clinical
trials [11, 18, 19]. Although the population from whom
these safety data are generated is different from the study
population of this protocol, women undergoing caesarean
section are expected to be at the same or higher risk of
AEs than women having a vaginal delivery. It is therefore
expected that a carbetocin RTS dose of 100 μg IM, when
used in women after vaginal delivery, will be efficacious
and have a safety profile that is equal to or better than the
well-characterized safety profile of 100 μg IV when used in
women following caesarean section.
The study has several strengths. It is a global, multi-
centred, randomized, double-blind, active comparator con-
trolled study. The active comparator is oxytocin, which is
the most commonly recommended drug for PPH prophy-
laxis and considered the current gold standard in WHO
guidelines. The 10 IU dose of oxytocin was chosen as this
is currently the most commonly used dose in clinical prac-
tice internationally when IM administration is practiced.
Blood loss of ≥1,000 mL is a primary endpoint in this trial,
as it was considered as one of the three critical endpoints
(together with blood transfusion and maternal death) for
the earlier 2007 WHO recommendations for PPH preven-
tion where outcomes were rated by an independent panel
[1]. We also used reliable estimates of prevalence of blood
loss ≥1,000 mL under active management with oxytocin
from different trials and systematic reviews. Additionally,
an external DSMC has been established for the ongoing
assessment of the risk-benefit ratio. One limitation of our
study is that the predicted sample size makes assumptions
that in reality might not hold. For example, if the efficacy
of oxytocin is much better than that of carbetocin RTS,
this would imply that non-inferiority is not likely to be
demonstrated and the trial should be stopped for futility. If
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oxytocin is just slightly better than carbetocin RTS, the
predicted sample size could have been underestimated,
but this is not likely given previous evidence [11].
Results of this trial will be extremely useful, particu-
larly in tropical settings, where cold storage is difficult to
achieve and maintain. Should this trial demonstrate that
carbetocin RTS is non-inferior to oxytocin in preventing
postpartum haemorrhage, in settings where the cold
chain cannot be guaranteed, oxytocin could be replaced
by carbetocin RTS as the uterotonic used during the
third stage of labour. In addition, and based on the tri-
partite agreement signed between WHO/HRP, Merck for
Mothers and Ferring Pharmaceuticals, carbetocin RTS
could be available in high-burden countries at a public
sector price comparable to oxytocin’s price. This could
have major implications for preventing PPH and a sub-
stantial impact on maternal survival worldwide.
Trial status
The trial has started recruitment in five countries. The
other five countries are expected to receive regulatory
authorities’ approval before April 2016.
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